{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:50:43Z","timestamp":1765828243265,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eprac.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:37:02Z","timestamp":1673091422000},"page":"193-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9855-5079","authenticated-orcid":false,"given":"Paola","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ashrafzadeh-Kian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua A.","family":"Bornhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-6217","authenticated-orcid":false,"given":"Alicia","family":"Algeciras-Schimnich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.eprac.2023.01.003_bib1","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1073\/pnas.1402218111","article-title":"Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis","volume":"111","author":"Tagliabracci","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2023.01.003_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","author":"Heijboer","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.eprac.2023.01.003_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"Consortium","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.eprac.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Florenzano","year":"2017","journal-title":"Bone Rep"},{"issue":"1","key":"10.1016\/j.eprac.2023.01.003_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"issue":"11","key":"10.1016\/j.eprac.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2023.01.003_bib7","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.eprac.2023.01.003_bib8","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.eprac.2023.01.003_bib9","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.eprac.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.eprac.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4614-0887-1_3","article-title":"FGF23 and syndromes of abnormal renal phosphate handling","volume":"728","author":"Bergwitz","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00774-021-01250-1","article-title":"Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23","volume":"39","author":"Ito","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.01.003_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-021-02329-7","article-title":"C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival","volume":"22","author":"Chu","year":"2021","journal-title":"BMC Nephrol. Apr 8"},{"issue":"4","key":"10.1016\/j.eprac.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"Wohrle","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.eprac.2023.01.003_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"bvab099","DOI":"10.1210\/jendso\/bvab099","article-title":"Diagnosis and management of tumor-induced osteomalacia: Perspectives from clinical experience","volume":"5","author":"Dahir","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eprac.2023.01.003_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.mce.2014.10.007","article-title":"Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli","volume":"399","author":"Ito","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.eprac.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1515\/cclm-2013-0208","article-title":"Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs","volume":"51","author":"Smith","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11255-013-0451-x","article-title":"FGF23 concentrations measured using \"intact\" assays similar but not interchangeable","volume":"45","author":"Sinha","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib23","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23","volume":"30","author":"Shimizu","year":"2012","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23\u00a0measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.eprac.2023.01.003_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.yexcr.2012.02.027","article-title":"Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease","volume":"318","author":"Quarles","year":"2012","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.eprac.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.mnh.0000172717.49476.80","article-title":"Role of fibroblast growth factor 23 in health and in chronic kidney disease","volume":"14","author":"Fukagawa","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"10.1016\/j.eprac.2023.01.003_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.eprac.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12882-021-02311-3","article-title":"Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD","volume":"22","author":"Kritmetapak","year":"2021","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1016\/j.eprac.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.eprac.2023.01.003_bib31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00774-011-0298-0","article-title":"Fibroblast growth factor 23 as a phosphotropic hormone and beyond","volume":"29","author":"Fukumoto","year":"2011","journal-title":"J\u00a0Bone Miner Metab"},{"issue":"6","key":"10.1016\/j.eprac.2023.01.003_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.eprac.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2023.01.003_bib34","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.eprac.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.01.003_bib36","first-page":"105","article-title":"Intact and C-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes?","volume":"12","author":"Sharma","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:10Z","timestamp":1761516850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1530891X23000022"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.01.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}